prodromale/preclinische fase van de ziekte van Alzheimer Alzheimers disease
Conditions
Interventions
None listed
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: For the healthy participant group: 1. No substantial memory complaints (according to the participant) 2. Age: between 30 and 95 years old 3. Right-handedness 4. Informed consent before participation in the study, For the MCI reference group (patients): 1. Diagnosis of MCI based on the latest research criteria (clinical assessment at the memory clinic (prof. Frans RJ Verhey): presence of at least a memory impairment, memory complaints expressed by the patient or informant, no problems in daily life functioning, no dementia and presence of biomarkers 2. Clinical Dementia Rating score of 0.5 (CDR distinguishes a stage of questionable dementia (CDR 0.5) from people termed healthy (CDR 0) and those with mild dementia (CDR 1) 3. Mini-Mental State Examination (MMSE) 23 and being mentally competent (in general, individuals with a MMSE 18 are considered mentally competent) 4. Age: between 60 and 85 years old 5. Right-handedness 6. Informed consent before participation in the study
Exclusion criteria
Exclusion criteria: 1. Reduced vision (glasses with > -6 or +6 corrected) 2. Psychoactive medication use 3. Abuse of alcohol and drugs 4. Cognitive impairment due to alcohol/drug abuse or abuse of other substances 5. Below average neuropsychological test results, in accordance with normative data, corrected for age, education and sex (Criterion for healthy participants only). 6. Past or present psychiatric or neurological disorders (major depression, schizophrenia, bipolar disorder, psychotic disorder (or treatment for it), epilepsy, stroke, Parkinson*s Disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Menière*s Disease, brain infections) (with exception of AD in the patient group) 7. Major vascular disorders (e.g. stroke) 8. Heart diseases or pacemakers 9. Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos) 10. Contraindications for pupil measurements (e.g. Cataracts, Glaucoma, detached retina*s, eye surgery involving the muscle, penetrating eye wounds, use of cholinesterase inhibitors, anticholinergic eye drop use, droopy eyelids preventing eye measurements)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures: - Cognition -The Blood-Oxygen-Level-Dependent (BOLD) respons predictors are objective (pupil) and subjective (questionnaires) stress measures Moderating variables are sex, age, education, reported sleep quality, caffeine use, AD related biomakers, estrogen levels and genetics. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures are: Alpha-amylase salivary activity over time Noradrenergic network connectivity -Structural brain measures -Blood markers of risk factors for Alzheimer's disease | — |
Countries
Netherlands
Outcome results
None listed